GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (FRA:2DT) » Definitions » Price-to-Owner-Earnings

Amneal Pharmaceuticals (FRA:2DT) Price-to-Owner-Earnings : 38.53 (As of May. 20, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Price-to-Owner-Earnings?

As of today (2025-05-20), Amneal Pharmaceuticals's share price is €6.55. Amneal Pharmaceuticals's Owner Earnings per Share (TTM) ended in Mar. 2025 was €0.17. It's Price-to-Owner-Earnings for today is 38.53.


The historical rank and industry rank for Amneal Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

FRA:2DT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.49   Med: 23.14   Max: 256.76
Current: 38

During the past 9 years, the highest Price-to-Owner-Earnings of Amneal Pharmaceuticals was 256.76. The lowest was 3.49. And the median was 23.14.


FRA:2DT's Price-to-Owner-Earnings is ranked worse than
66.67% of 447 companies
in the Drug Manufacturers industry
Industry Median: 24.57 vs FRA:2DT: 38.00

As of today (2025-05-20), Amneal Pharmaceuticals's share price is €6.55. Amneal Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.04. Therefore, Amneal Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-20), Amneal Pharmaceuticals's share price is €6.55. Amneal Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was €0.60. Therefore, Amneal Pharmaceuticals's PE Ratio without NRI for today is 10.88.

During the past 9 years, Amneal Pharmaceuticals's highest PE Ratio without NRI was 1320.00. The lowest was 2.00. And the median was 6.92.


Amneal Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Amneal Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Price-to-Owner-Earnings Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - 17.75 - 54.50 45.94

Amneal Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 230.00 45.94 42.35

Competitive Comparison of Amneal Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Price-to-Owner-Earnings falls into.


;
;

Amneal Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Amneal Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.55/0.17
=38.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amneal Pharmaceuticals  (FRA:2DT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Amneal Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Amneal Pharmaceuticals Headlines

No Headlines